C

현대바이오랜드

052260KOSDAQ기타 화학제품 제조업

47.5 / 100

Reference Date: 2026-06-10

Financial Score21.0 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Plunged 17.5% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Hyundai BioLand operates in various sectors including cosmetics, health supplements, pharmaceutical ingredients, medical devices, and brand distribution, leveraging natural bio-materials. The company focuses on developing high-value products such as hyaluronic acid and plant-based collagen, while expanding global partnerships. It emphasizes R&D to meet environmental regulations and consumer trends, and is actively growing its market presence through innovative technologies and strategic collaborations.

Number of Employees

342people

Average Salary

66.9M KRW

Score Calculation Basis

Detailed Financial Score

PER
460.00Industry Average 16.500.0Point

27.9x industry avg (risky)

PBR
0.81Industry Average 1.135.5Point

Lower than industry avg (good)

ROE
0.18Industry Average 4.551.0Point

Well below industry avg

Debt Ratio
1.84Industry Average 8.138.0Point

Half of industry avg (excellent)

Trend 2023~20256.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲13.4% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲54.3% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 3.5% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 3,680Won52-week high 5,34052-week low 3,680
1-month return0.0Point

1m -17.49% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]2026-05-29
  • Neutral분기보고서 (2026.03)2026-05-15